Ind Swift Ltd
NSE:INDSWFTLTD

Watchlist Manager
Ind Swift Ltd Logo
Ind Swift Ltd
NSE:INDSWFTLTD
Watchlist
Price: 15.71 INR 5.79% Market Closed
Market Cap: ₹850.9m

Relative Value

INDSWFTLTD doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of INDSWFTLTD.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INDSWFTLTD Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

INDSWFTLTD Competitors Multiples
Ind Swift Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Ind Swift Ltd
NSE:INDSWFTLTD
850.9m INR 0.2 1.3 25.5 63.8
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57 38.2 41
US
Johnson & Johnson
NYSE:JNJ
564.7B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
282.5B CHF 4.6 30.3 12.8 14.9
US
Merck & Co Inc
NYSE:MRK
294.9B USD 4.5 16.2 10.1 11.8
CH
Novartis AG
SIX:NOVN
226B CHF 5.2 20.3 12.7 16.4
UK
AstraZeneca PLC
LSE:AZN
212.5B GBP 5.1 31.6 15.1 22.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.9 9 10.5
US
Pfizer Inc
NYSE:PFE
153.2B USD 2.4 19.7 7.4 9.8
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 2.4 19.4 6.9 9
P/E Multiple
Earnings Growth PEG
IN
Ind Swift Ltd
NSE:INDSWFTLTD
Average P/E: 23
1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
57
54%
1.1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.3
29%
1
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
CH
Novartis AG
SIX:NOVN
20.3
17%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
2%
6.4
US
Pfizer Inc
NYSE:PFE
19.7
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
19.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Ind Swift Ltd
NSE:INDSWFTLTD
Average EV/EBITDA: 44.1
25.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
7%
1.4
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
1%
9
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-9%
N/A